AtriCure, Inc. ( ATRC ) NASDAQ Global Market

Cena: 37.58 ( 5.16% )

Aktualizacja 08-22 21:58
NASDAQ Global Market
Branża: Medical - Instruments & Supplies
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Atricure, Inc. opracowuje, produkuje i sprzedaje urządzenia do chirurgicznej ablacji tkanki i układów serca oraz nerwów międzyżebrowych w ośrodkach medycznych w Stanach Zjednoczonych, Europie, Azji i na arenie międzynarodowej. Firma oferuje Clamps Synergy Izolator, jednorazowe produkty jednorazowe; Wielofunkcyjne długopisy i liniowe urządzenia ablacyjne, takie jak urządzenie maksymalne, które umożliwia chirurgom ocenę arytmii serca, wykonywanie tymczasowego stymulacji serca, wykrywania i stymulacji oraz ablation tkanki serca z tym samym urządzeniem; oraz urządzenie Coolrail, które umożliwia użytkownikom wykonywanie dłuższych liniowych linii ablacji. Zapewnia również system krioablacji kriokowania, który umożliwia użytkownikowi tworzenie liniowych ablacji o różnych długościach; System krzepnięcia z przewodnikiem EPI, jednorazowe urządzenie jednorazowe stosowane w leczeniu objawowych, odpornych na leki i długotrwałych trwałej migotania przedsionków; System Atriclip, wszczepialne urządzenie sprzężone z jednorazowym zastosowaniem jednorazowego użytku; oraz system Lariat, rozwiązanie oparte na szwach do zamykania tkanek miękkich kompatybilnych z szeregiem anatomicznych kształtów. Ponadto firma sprzedaje dyspozycje Lumitip w celu oddzielenia tkanek, aby zapewnić dostęp do kluczowych struktur anatomicznych, które są skierowane do ablacji; Przewodniki Glidepath do umieszczania zacisków; Subtelne kaniule wspierające dostęp do cewników epi-sens; oraz różne instrumenty chirurgii serca wielokrotnego użytku, które są stosowane podczas chirurgicznych zabiegów naprawy lub wymiany niektórych zaworów serca. Sprzedaje i sprzedaje swoje produkty za pośrednictwem niezależnych dystrybutorów i bezpośrednich pracowników sprzedaży. Firma została zarejestrowana w 2000 roku i ma siedzibę w Mason, Ohio.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 1 200
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 96.994
Ilość akcji: Brak danych
Debiut giełdowy: 2005-08-05
WWW: https://www.atricure.com
CEO: Mr. Michael H. Carrel
Adres: 7555 Innovation Way
Siedziba: 45040 Mason
ISIN: US04963C2098
Wskaźniki finansowe
Kapitalizacja (USD) 1 867 530 105
Aktywa: 615 068 000
Cena: 37.58
Wskaźnik Altman Z-Score: 6.7
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -48.8
Ilość akcji w obrocie: 97%
Średni wolumen: 525 038
Ilość akcji 49 701 400
Wskaźniki finansowe
Przychody TTM 447 573 000
Zobowiązania: 150 047 000
Przedział 52 tyg.: 24.48 - 43.11
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -0.8
P/E branży: 29.7
Beta: 1.408
Raport okresowy: 2025-10-28
WWW: https://www.atricure.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Angela L. Wirick CPA Chief Financial Officer 841 537 1978
Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer 777 660 1972
Mr. Karl S. Dahlquist CCEP, J.D. Chief Legal Officer 762 391 1971
Mr. Salvatore Privitera J.D. Chief Technical Officer 758 805 1967
Mr. Justin J. Noznesky Chief Marketing & Strategy Officer 644 729 1978
Ms. Deborah Yount Chief Human Resources Officer 498 361 1966
Mr. Michael H. Carrel Chief Executive Officer, President & Director 2 010 824 1971
Mr. Douglas J. Seith Chief Operating Officer 1 201 146 1966
Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications 0 0
Lista ETF z ekspozycją na akcje AtriCure, Inc.
Symbol ETF Ilość akcji Wartość
IWM 1 164 341 40 868 380
VB 1 148 309 37 630 085
VBK 645 346 21 147 988
IWO 425 610 14 938 927
IHI 249 234 8 748 107
VTWO 246 449 8 076 133
SCHA 232 848 8 094 991
VHT 154 690 5 069 191
DFAS 127 205 4 464 895
FESM 111 724 3 711 471
DFAC 102 125 3 584 587
XHE 87 620 3 175 276
ZPRR.DE 76 490 2 353 088
R2SC.L 76 490 2 036 252
R2US.L 76 490 2 687 093
FYC 70 996 2 085 152
HEAL.L 61 564 2 160 881
2B78.DE 61 564 1 890 339
DRDR.L 61 564 1 635 527
ITOT 60 684 2 130 002
FYX 46 965 1 379 362
VTWG 42 784 1 402 031
CSUSS.MI 33 880 1 040 299
CUSS.L 33 880 1 189 185
SXRG.DE 33 880 1 040 299
CUS1.L 33 880 900 070
PSC 33 463 1 174 551
VFMO 32 954 1 079 902
AVSC 32 260 1 133 293
SCHB 31 430 1 099 977
PRFZ 29 565 1 038 618
XRSG.L 29 373 78 127 788
XRS2.DE 29 373 902 842
XRSU.L 29 373 1 030 995
AGES.L 27 814 738 913
2B77.DE 27 814 854 034
AGED.L 27 814 976 262
ESML 26 621 935 195
GSSC 26 569 848 082
RSSL 24 727 867 917
FHLC 21 395 710 741
SMLF 18 971 665 889
ONEQ 17 771 590 352
BBSC 17 551 616 040
EES 14 023 492 207
ETHO 14 004 491 540
ISCG 13 386 469 863
WSCR.L 13 066 414 596
IWV 11 958 419 733
ESGV 10 116 331 501
FAD 9 161 269 058
XSU.TO 8 366 405 937
OMFS 7 326 257 362
DFAU 7 277 255 422
UMDV.AS 6 799 238 638
SMLV 6 642 235 914
UWM 4 898 171 919
URTY 4 054 142 295
VTHR 3 801 124 558
FLQS 3 730 131 034
DCOR 2 627 92 207
TILT 2 464 86 486
ISCB 2 322 81 501
EWSA.AS 2 249 78 937
CBUG.DE 2 249 69 054
DRUP.DE 2 242 67 953
UNIC.L 2 242 77 579
DTEC.L 2 242 58 789
VMO.TO 2 156 96 404
DFSU 1 767 62 021
ZPRV.DE 1 656 44 376
USSC.L 1 656 50 675
BUYO 1 313 46 086
HART 1 289 45 243
XUU.TO 1 100 53 363
QQQS 1 087 38 186
V3AA.L 548 17 957
V3AB.L 548 13 608
V3AL.L 548 17 957
USUE.DE 483 16 961
USFM.L 483 16 961
SCDS 464 16 286
XBAL.TO 350 16 996
XUH.TO 162 5 704
HDG 59 2 070
XTR.TO 7 230
RTYS.L 0 161 159
PZW.TO 0 4 855
SC0K.DE 0 141 207
Wiadomości dla AtriCure, Inc.
Tytuł Treść Źródło Aktualizacja Link
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2025-05-15 15:00:44 Czytaj oryginał (ang.)
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com 2025-04-30 01:34:09 Czytaj oryginał (ang.)
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-04-29 22:30:40 Czytaj oryginał (ang.)
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago. zacks.com 2025-04-29 22:10:37 Czytaj oryginał (ang.)
AtriCure Reports First Quarter 2025 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As. businesswire.com 2025-04-29 20:01:00 Czytaj oryginał (ang.)
AtriCure to Announce First Quarter 2025 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list. businesswire.com 2025-04-08 12:00:00 Czytaj oryginał (ang.)
AtriCure to Host Analyst & Investor Day on March 26, 2025 MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa. businesswire.com 2025-03-12 10:00:00 Czytaj oryginał (ang.)
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-02-13 15:01:22 Czytaj oryginał (ang.)
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com 2025-02-13 00:46:43 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-02-12 20:31:11 Czytaj oryginał (ang.)
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago. zacks.com 2025-02-12 20:16:19 Czytaj oryginał (ang.)
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key fran. businesswire.com 2025-02-12 18:01:00 Czytaj oryginał (ang.)
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. zacks.com 2025-02-11 12:20:28 Czytaj oryginał (ang.)
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-05 13:05:16 Czytaj oryginał (ang.)
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin. businesswire.com 2025-01-22 10:00:00 Czytaj oryginał (ang.)
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio. businesswire.com 2024-12-23 10:00:00 Czytaj oryginał (ang.)
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-10-30 01:53:08 Czytaj oryginał (ang.)
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-10-29 22:01:13 Czytaj oryginał (ang.)
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago. zacks.com 2024-10-29 20:11:07 Czytaj oryginał (ang.)
AtriCure Reports Third Quarter 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “During the quarter, we launched sev. businesswire.com 2024-10-29 18:01:00 Czytaj oryginał (ang.)
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks. zacks.com 2024-10-16 17:15:25 Czytaj oryginał (ang.)
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation. businesswire.com 2024-10-15 12:00:00 Czytaj oryginał (ang.)
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology. zacks.com 2024-10-11 15:30:24 Czytaj oryginał (ang.)
AtriCure to Announce Third Quarter 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in. businesswire.com 2024-10-08 12:00:00 Czytaj oryginał (ang.)
Faisal Al Bannai In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would… time.com 2024-09-05 11:23:51 Czytaj oryginał (ang.)
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device. zacks.com 2024-08-28 17:15:34 Czytaj oryginał (ang.)
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of. businesswire.com 2024-08-27 12:00:00 Czytaj oryginał (ang.)
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib. zacks.com 2024-08-23 17:10:48 Czytaj oryginał (ang.)
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com 2024-07-31 04:01:03 Czytaj oryginał (ang.)
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-07-30 22:31:19 Czytaj oryginał (ang.)
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. zacks.com 2024-07-30 22:11:11 Czytaj oryginał (ang.)
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of. businesswire.com 2024-07-29 12:00:00 Czytaj oryginał (ang.)
AtriCure (ATRC) Gains China Approval for AtriClip LAA System AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion. zacks.com 2024-07-24 15:15:38 Czytaj oryginał (ang.)
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake. investorplace.com 2024-06-28 10:50:00 Czytaj oryginał (ang.)
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may acc. businesswire.com 2024-05-15 12:00:00 Czytaj oryginał (ang.)